- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study is testing a new eye treatment called JNJ-81201887 for a condition called Geographic Atrophy (GA). GA is a serious eye problem linked to ageing that can cause blurry vision. Researchers want to see if this new treatment can slow down the worsening of GA.
For: Geographic AtrophyNetherlands · Belgium · Germany - RecruitingPHASE2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study looks at the long-term safety of a new eye treatment, JNJ-81201887, for geographic atrophy, a type of macular degeneration. It checks how people who received this treatment in earlier studies are doing over time.
For: Geographic Atrophy · Macular DegenerationUnited States · Australia · Belgium